{"id":9849,"date":"2026-04-03T20:34:39","date_gmt":"2026-04-03T17:34:39","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9849"},"modified":"2026-04-03T20:34:39","modified_gmt":"2026-04-03T17:34:39","slug":"global-blood-pressure-targets-and-treatment-thresholds-across-major-guidelines-2025-update","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/global-blood-pressure-targets-and-treatment-thresholds-across-major-guidelines-2025-update\/","title":{"rendered":"Global Blood Pressure Targets and Treatment Thresholds Across Major Guidelines (2025 Update)"},"content":{"rendered":"
Global Blood Pressure Targets and Treatment Thresholds Across Major Guidelines (2025 Update)<\/div>\n
<\/div>\n
AHA\/ACC 2025 (USA)<\/div>\n
\u2022 Start treatment at \u2265130\/80 mm Hg<\/span><\/div>\n
\u2022 Target:<\/span><\/div>\n
\u2022 <130\/80 mm Hg for most<\/span><\/div>\n
\u2022 Encourage <120 SBP (if tolerated, especially high-risk)<\/span><\/div>\n
\u2022 Reflects shift toward intensive BP control<\/span><\/div>\n
<\/div>\n
ESC 2024 \/ ESH 2023 (Europe)<\/div>\n
\u2022 Classification:<\/span><\/div>\n
\u2022 130\u2013139 \/ 85\u201389 \u2192 \u201chigh-normal\u201d<\/span><\/div>\n
\u2022 Treatment:<\/span><\/div>\n
\u2022 Pharmacotherapy mainly for high-risk patients<\/span><\/div>\n
\u2022 Targets:<\/span><\/div>\n
\u2022 Generally <130\/80 mm Hg<\/span><\/div>\n
\u2022 \u2757 Avoid aggressive lowering:<\/span><\/div>\n
\u2022 Do NOT target <120 SBP or <70 DBP<\/span><\/div>\n
<\/div>\n
ISH 2020 (Global)<\/div>\n
\u2022 Initial goal:<\/span><\/div>\n
\u2022 Reduce BP by \u226520\/10 mm Hg<\/span><\/div>\n
\u2022 Targets:<\/span><\/div>\n
\u2022 Most: <140\/90 mm Hg<\/span><\/div>\n
\u2022 <65 yrs: <130\/80 (but >120\/70)<\/span><\/div>\n
\u2022 \u226565 yrs: <140\/90, individualized<\/span><\/div>\n
<\/div>\n
NICE 2024 (UK)<\/div>\n
\u2022 Clinic targets:<\/span><\/div>\n
\u2022 <80 yrs: <140\/90 mm Hg<\/span><\/div>\n
\u2022 \u226580 yrs: <150\/90 mm Hg<\/span><\/div>\n
\u2022 Home \/ ambulatory BP:<\/span><\/div>\n
\u2022 Targets 5 mm Hg lower<\/span><\/div>\n
\u2022 (<135\/85 or <145\/85)<\/span><\/div>\n
<\/div>\n
WHO 2022<\/div>\n
\u2022 Start treatment after confirmed HTN + lifestyle<\/span><\/div>\n
\u2022 Target:<\/span><\/div>\n
\u2022 <140\/90 mm Hg<\/span><\/div>\n
\u2022 Focus:<\/span><\/div>\n
\u2022 Practical global implementation<\/span><\/div>\n
\u2022 Control rates still <14% worldwide<\/span><\/div>\n
<\/div>\n
KDIGO 2024 (CKD-specific)<\/div>\n
\u2022 Target:<\/span><\/div>\n
\u2022 SBP <120 mm Hg<\/span><\/div>\n
\u2022 Based on:<\/span><\/div>\n
\u2022 Intensive control benefits in CKD<\/span><\/div>\n
\u2022 More aggressive than general guidelines<\/span><\/div>\n
<\/div>\n
Acute Settings (Important)<\/div>\n
\u2022 Hypertensive emergency:<\/span><\/div>\n
\u2022 \u2193 SBP \u226425% in first hour<\/span><\/div>\n
\u2022 Then ~160\/100 in 2\u20136 hours<\/span><\/div>\n
\u2022 Gradual normalization over 24\u201348 hours<\/span><\/div>\n
\u2022 Intracerebral hemorrhage:<\/span><\/div>\n
\u2022 Target SBP <140 mm Hg<\/span><\/div>\n
\u2022 Safe and reduces hematoma expansion<\/span><\/div>\n
<\/div>\n
\ud83c\udfaf Key Clinical Insights<\/div>\n
\u2022 Global convergence toward:<\/span><\/div>\n
\u2022 <130\/80 mm Hg in appropriate patients<\/span><\/div>\n
\u2022 Differences:<\/span><\/div>\n
\u2022 Europe \u2192 more conservative (avoid <120)<\/span><\/div>\n
\u2022 USA & KDIGO\u201dInternational kidney guidelines\u2192 more intensive<\/span><\/div>\n
\u2022 ISH \/ WHO \u2192 pragmatic for global settings<\/span><\/div>\n
<\/div>\n
\ud83e\udde0 Bottom Line<\/div>\n
\u2022 One size does NOT fit all<\/span><\/div>\n
\u2022 Individualize based on:<\/span><\/div>\n
\u2022 Age<\/span><\/div>\n
\u2022 Risk profile<\/span><\/div>\n
\u2022 Tolerance<\/span><\/div>\n
\u2022 CKD status<\/span><\/div>\n
<\/div>\n
\ud83d\udc49 Practical optimal range:<\/div>\n
\u2022 Most patients: SBP 120\u2013130 mm Hg<\/span><\/div>\n
\u2022 Avoid:<\/span><\/div>\n
\u2022 <120 (unless carefully selected)<\/span><\/div>\n
\u2022 \u2265130 (associated with higher risk)<\/span><\/div>\n
<\/div>\n
\u00a0(Jordan cardiac society national protocols):<\/div>\n
\u2022 Adopt a pragmatic hybrid model:<\/span><\/div>\n
\u2022 General Population -Hypertension Definition\u00a0 : <140\/90 mm Hg<\/span><\/div>\n
\u2022 High-risk (ASCVD, diabetes, CKD): <130\/80 mm Hg<\/span><\/div>\n
\u2022 Suitable for mixed-resource systems<\/span><\/div>\n
\u2022 Focus on high-yield risk groups)<\/span><\/div>\n
Reference:<\/div>\n
KDIGO Clinical Practice Guideline (2024) \u2014 Blood Pressure in CKD (as summarized in AHA\/ACC 2025 commentary)<\/div>\n
<\/div>\n
Link:<\/div>\n
–https:\/\/pubmed.ncbi.nlm.nih.gov\/41805831\/<\/a><\/div>\n
–https:\/\/kdigo.org\/guidelines\/blood-pressure-in-ckd\/<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Global Blood Pressure Targets and Treatment Thresholds Across Major Guidelines (2025 Update) AHA\/ACC 2025 (USA) \u2022 Start treatment at \u2265130\/80 mm Hg \u2022 Target: \u2022 <130\/80 mm Hg for most \u2022 Encourage <120 SBP (if tolerated, especially high-risk) \u2022 Reflects shift toward intensive BP control ESC 2024 \/ ESH 2023 (Europe) \u2022 Classification: \u2022 130\u2013139 […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9849","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9849"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9849\/revisions"}],"predecessor-version":[{"id":9850,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9849\/revisions\/9850"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}